Global Gilenya Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Gilenya Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Gilenya is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
Gilenya report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gilenya market is projected to reach US$ 934.9 million in 2029, increasing from US$ 2013 million in 2022, with the CAGR of -8.7% during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
The Gilenya market is primarily driven by the growing demand for effective treatments for multiple sclerosis (MS), particularly relapsing forms of the disease. Gilenya (fingolimod) is an oral medication that modulates immune system responses, aiming to reduce relapses and slow down disease progression. The increasing prevalence of MS and the need for therapies that offer convenience and improved quality of life contribute to market growth. Moreover, the shift from injectable to oral treatments and the potential to decrease relapse rates further propel adoption. However, challenges include potential cardiac effects during the initial dose and the need for monitoring patients for safety. Navigating the competitive landscape of MS treatments and addressing affordability and access barriers for a wider patient population are ongoing concerns. The market's success hinges on continuous research to enhance safety profiles, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to optimize MS management while addressing the evolving challenges associated with Gilenya therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gilenya market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Segment by Type
28 Capsules/Box
96 Capsules/Box
Retail Pharmacy
Hospital Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gilenya market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gilenya, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gilenya industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gilenya in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gilenya introduction, etc. Gilenya Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gilenya market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Gilenya report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gilenya market is projected to reach US$ 934.9 million in 2029, increasing from US$ 2013 million in 2022, with the CAGR of -8.7% during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
The Gilenya market is primarily driven by the growing demand for effective treatments for multiple sclerosis (MS), particularly relapsing forms of the disease. Gilenya (fingolimod) is an oral medication that modulates immune system responses, aiming to reduce relapses and slow down disease progression. The increasing prevalence of MS and the need for therapies that offer convenience and improved quality of life contribute to market growth. Moreover, the shift from injectable to oral treatments and the potential to decrease relapse rates further propel adoption. However, challenges include potential cardiac effects during the initial dose and the need for monitoring patients for safety. Navigating the competitive landscape of MS treatments and addressing affordability and access barriers for a wider patient population are ongoing concerns. The market's success hinges on continuous research to enhance safety profiles, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to optimize MS management while addressing the evolving challenges associated with Gilenya therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gilenya market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Segment by Type
28 Capsules/Box
96 Capsules/Box
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gilenya market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gilenya, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gilenya industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gilenya in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gilenya introduction, etc. Gilenya Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gilenya market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices